S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease
- PMID: 22786469
- DOI: 10.1253/circj.cj-12-0093
S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease
Abstract
Background: S100A12, a calgranulin family protein released from white blood cells, is involved in inflammatory cardiovascular disease. It was hypothesized that the plasma level of S100A12 can be used to predict outcome in patients with chronic coronary artery disease (CAD). The purpose of this study was to clarify the clinical significance of S100A12 in patients with stable CAD.
Methods and results: A total of 652 patients with stable CAD were studied. All patients underwent percutaneous coronary intervention and successful revascularization. Major adverse cardiovascular events (MACE) were defined as a composite of events of CHF, recurrence of angina pectoris, acute myocardial infarction, stroke, critical arrhythmia, intervention to peripheral arteries and cardiac death. The mean follow-up period was 973±639 days. MACE occurred in 108 patients (16.6%). Plasma S100A12 level had a significant positive correlation with high-sensitivity C-reactive protein (hs-CRP) level. On Kaplan-Meier curve analysis the incidence of MACE was significantly different among S100A12 quartiles (P=0.026). The highest S100A12 quartile (Q4) had a significantly higher MACE rate than the lowest quartile (Q1) (P=0.002). In contrast, hs-CRP was not significant for predicting MACE in the present subjects (P=0.074). A Cox proportional hazard model showed that S100A12 was an independent factor for predicting MACE in multivariate models.
Conclusions: S100A12 could be a novel biomarker for predicting cardiovascular events for predicting MACE in patients with stable CAD.
Similar articles
-
Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study).Clin Chim Acta. 2015 May 20;445:93-100. doi: 10.1016/j.cca.2015.03.029. Epub 2015 Mar 27. Clin Chim Acta. 2015. PMID: 25818243
-
Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases.Heart Vessels. 2012 Jul;27(4):344-51. doi: 10.1007/s00380-011-0163-z. Epub 2011 Jun 11. Heart Vessels. 2012. PMID: 21667051
-
High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus.Cardiovasc Diabetol. 2019 Dec 17;18(1):171. doi: 10.1186/s12933-019-0974-2. Cardiovasc Diabetol. 2019. PMID: 31847896 Free PMC article.
-
Predicting CAD events: C-reactive protein a marker for atherosclerotic risk.Nurse Pract. 2004 Jun;29(6):14-5, 19-27; quiz 27-9. doi: 10.1097/00006205-200406000-00004. Nurse Pract. 2004. PMID: 15257119 Review. No abstract available.
-
Metabolic biomarkers for predicting cardiovascular disease.Vasc Health Risk Manag. 2013;9:37-45. doi: 10.2147/VHRM.S30378. Epub 2013 Jan 29. Vasc Health Risk Manag. 2013. PMID: 23386789 Free PMC article. Review.
Cited by
-
Bioinformatics analysis to identify potential biomarkers and therapeutic targets for ST-segment-elevation myocardial infarction-related ischemic stroke.Front Neurol. 2022 Aug 11;13:894289. doi: 10.3389/fneur.2022.894289. eCollection 2022. Front Neurol. 2022. PMID: 36034287 Free PMC article.
-
Analysis of region specific gene expression patterns in the heart and systemic responses after experimental myocardial ischemia.Oncotarget. 2017 May 17;8(37):60809-60825. doi: 10.18632/oncotarget.17955. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 28977827 Free PMC article.
-
Amlexanox reduces new-onset atrial fibrillation risk in sepsis by downregulating S100A12: a Mendelian randomization study.Front Cardiovasc Med. 2024 Oct 9;11:1401314. doi: 10.3389/fcvm.2024.1401314. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39444551 Free PMC article.
-
Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors.Drug Dev Res. 2022 Sep;83(6):1257-1269. doi: 10.1002/ddr.21971. Epub 2022 Jul 4. Drug Dev Res. 2022. PMID: 35781678 Free PMC article. Review.
-
Weighted gene co-expression network analysis identifies specific modules and hub genes related to coronary artery disease.BMC Cardiovasc Disord. 2016 Mar 5;16:54. doi: 10.1186/s12872-016-0217-3. BMC Cardiovasc Disord. 2016. PMID: 26944061 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous